Epigenetic silencing of MEIS2 in prostate cancer recurrence

BACKGROUND: Current diagnostic and prognostic tools for prostate cancer (PC) are suboptimal, resulting in overdiagnosis and overtreatment of clinically insignificant tumors. Thus, to improve the management of PC, novel biomarkers are urgently needed. RESULTS: In this study, we integrated genome-wide...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Clin Epigenetics
Main Authors: Nørgaard, Maibritt, Haldrup, Christa, Bjerre, Marianne Trier, Høyer, Søren, Ulhøi, Benedicte, Borre, Michael, Sørensen, Karina D.
Formato: Artigo
Idioma:Inglês
Publicado: BioMed Central 2019
Assuntos:
Research
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6805635/
https://ncbi.nlm.nih.gov/pubmed/31640805
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-019-0742-x
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares